Crizotinib (Xalkori™)

  • Trial Availability: USA
  • Tumor Target: Recurrent Meningioma
  • Treatment by: Pill - Oral
  • Recruiting Trial: NCT02465060

PI3K/Akt/mTOR signaling pathway
Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual mTOR Complex 1 and 2 inhibitor, mTORC1 and mTORC2) Synonym: PF-02341066
Chemical Formula: C21H22Cl2FN5O
Synonym: PF02341066; PF-02341066; PF 02341066; PF2341066; PF-2341066; PF 2341066; Crizotinib; US brand name: Xalkori;
IUPAC/Chemical Name: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
Solubility: Soluble in DMSO, not in water. Dimethyl Sulfoxide (DMSO) is an organosulfur compound with the formula (CH3)2SO.
Inhibitor: inhibits the membrane receptor MET and activation of the MET signaling pathway
Side Effects: fatigue, nausea, mucositis, rash, constipation, vomiting, dyspnea and cough
Also In Use For: Breast Cancer, solid tumor cancer
Dose: Single doses up to 100 mg two times a day, but study duration 1 month
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services,, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017